ArticleDiagnostics (Basel, Switzerland)2022
Deep Learning Prediction of Response to Anti-VEGF among Diabetic Macular Edema Patients: Treatment Response Analyzer System (TRAS).
Article in Diagnostics (Basel, Switzerland), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed.
- Multimodal deep learning prediction of treatment response to anti-vascular endothelial growth factor in diabetic macular oedema.Eye (London, England) · 2026Article
- The evolving role of artificial intelligence in optimizing treatment and patient selection in diabetic macular edema.Indian journal of ophthalmology · 2026Review
- The Central Role of Oxidative Stress in Diabetic Retinopathy: Advances in Pathogenesis, Diagnosis, and Therapy.Diagnostics (Basel, Switzerland) · 2026Review
- Artificial intelligence for precision therapeutics in age-related macular degeneration: current advances, challenges, and future directions.Frontiers in artificial intelligence · 2026Review
- Therapeutic approaches to diabetic macular edema assessed using optical coherence tomography and optical coherence tomography angiography.International journal of ophthalmology · 2026Review
- Artificial Intelligence in Diabetic Retinopathy and Diabetic Macular Edema: A Narrative Review.Bioengineering (Basel, Switzerland) · 2025Review
- Diagnostic Accuracy of Artificial Intelligence in Predicting Anti-VEGF Treatment Response in Diabetic Macular Edema: A Systematic Review and Meta-Analysis.Journal of clinical medicine · 2025Review
- AI-Based Response Classification After Anti-VEGF Loading in Neovascular Age-Related Macular Degeneration.Diagnostics (Basel, Switzerland) · 2025Article
- Ensemble machine learning algorithm for anti-VEGF treatment efficacy prediction in diabetic macular edema.BMC ophthalmology · 2025Article
- Application of deep learning algorithm for judicious use of anti-VEGF in diabetic macular edema.Scientific reports · 2025Article
- Differences in Artificial Intelligence-Based Macular Fluid Parameters Between Clinical Stages of Diabetic Macular Edema and Their Relationship with Visual Acuity.Journal of clinical medicine · 2025Article
- Construction of a predictive model for the efficacy of anti-VEGF therapy in macular edema patients based on OCT imaging: a retrospective study.Frontiers in medicine · 2025Article
- Development and validation of CNN-MLP models for predicting anti-VEGF therapy outcomes in diabetic macular edema.Scientific reports · 2024Article
- Novel artificial intelligence algorithms for diabetic retinopathy and diabetic macular edema.Eye and vision (London, England) · 2024Review
- Deep learning in optical coherence tomography: Where are the gaps?Clinical & experimental ophthalmology · 2023Review
- Artificial Intelligence and Glaucoma: Going Back to Basics.Clinical ophthalmology (Auckland, N.Z.) · 2023Review
- Predictive, preventive, and personalized management of retinal fluid via computer-aided detection app for optical coherence tomography scans.The EPMA journal · 2022Article
- Artificial Intelligence in Eye Disease: Recent Developments, Applications, and Surveys.Diagnostics (Basel, Switzerland) · 2022Article
- Evaluating the utility of deep learning for predicting therapeutic response in diabetic eye disease.Frontiers in ophthalmology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Diabetic macular edema (DME) is the most common cause of visual impairment among patients with diabetes mellitus. Anti-vascular endothelial growth factors (Anti-VEGFs) are considered the first line in its management. The aim of this research has been to develop a deep learning (DL) model for predicting response to intravitreal anti-VEGF injections among DME patients. The research included treatment naive DME patients who were treated with anti-VEGF. Patient's pre-treatment and post-treatment clinical and macular optical coherence tomography (OCT) were assessed by retina specialists, who annotated pre-treatment images for five prognostic features. Patients were also classified based on their response to treatment in their post-treatment OCT into either good responder, defined as a reduction of thickness by >25% or 50 µm by 3 months, or poor responder. A novel modified U-net DL model for image segmentation, and another DL EfficientNet-B3 model for response classification were developed and implemented for predicting response to anti-VEGF injections among patients with DME. Finally, the classification DL model was compared with different levels of ophthalmology residents and specialists regarding response classification accuracy. The segmentation deep learning model resulted in segmentation accuracy of 95.9%, with a specificity of 98.9%, and a sensitivity of 87.9%. The classification accuracy of classifying patients' images into good and poor responders reached 75%. Upon comparing the model's performance with practicing ophthalmology residents, ophthalmologists and retina specialists, the model's accuracy is comparable to ophthalmologist's accuracy. The developed DL models can segment and predict response to anti-VEGF treatment among DME patients with comparable accuracy to general ophthalmologists. Further training on a larger dataset is nonetheless needed to yield more accurate response predictions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.